Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Drug Discovery
- Viral Infection
- Antibody
- Respiratory
- Vaccine
- Disease
- Therapeutic
- Arthritis
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 311941
License Grant
Licensor granted Bermuda Licensee an exclusive, sublicensable, worldwide license to certain intellectual property rights to make, use, develop and commercialize mavrilimumab. Under the original Agreement, the Licensee also acquired reference rights to relevant manufacturing and regulatory documents and Licensor’s existing supply of mavrilimumab drug substance and product. This amendment allows the Licensee to establish a new coronavirus field and defer the payment of certain development and regulatory milestones as applied to the new coronavirus field.
License Property
Mavrilimumab is a monoclonal antibody that antagonizes granulocyte-macrophage colony stimulating factor, or GM-CSF.
Licensor is a biopharmaceutical company known for its vaccine technology and offers biological products, therapeutic and preventive medicines.
Field of Use
The field of use is in the treatment of coronavirus 2019, or COVID-19, a pneumonia and hyperinflammation disease and giant cell arteritis, or GCA, a chronic inflammatory disease of the medium-to-large arteries.
Licensee is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need. Licensee has a pipeline of clinical-stage product candidates that are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways that are implicated across a spectrum of diseases.
IPSCIO Record ID: 306663
License Grant
The Licensee entered into a worldwide nonexclusive License Agreement with the Licensor, the primary agency of the United States government responsible for biomedical and public health research, for the use of certain patents and tangible materials to be used in the development and commercialization of a vaccine for the SARS-CoV-2 virus.
License Property
The focus is on the development of a vaccine for the SARS-CoV-2 virus and other strains of coronavirus using patented and patent-pending technology.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic.
Field of Use
Licensee focus is on developing novel antibiotics against infectious diseases; especially a vaccine for the SARS-CoV-2 virus and other strains of coronavirus using patented and patent-pending technology. The goal is accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.
IPSCIO Record ID: 231728
License Grant
The Licensor granted the Bermudan Licensee an exclusive, sublicensable, worldwide license to certain intellectual property rights to make, use, develop and commercialize mavrilimumab. a human monoclonal antibody for the treatment of rheumatoid arthritis.
License Property
The Licensor also granted reference rights to relevant manufacturing and regulatory documents and existing supply of mavrilimumab drug substance and product.
Field of Use
The Bermudan Licensee is obligated to use commercially reasonable efforts to develop and commercialize the licensed products. The investigational drug may be used as a rheumatoid arthritis treatment.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
